186 related articles for article (PubMed ID: 34310723)
21. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
[TBL] [Abstract][Full Text] [Related]
23. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract][Full Text] [Related]
24. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.
Andersen KØ; Detlefsen S; Brusgaard K; Christesen HT
Front Endocrinol (Lausanne); 2024; 15():1351624. PubMed ID: 38868744
[TBL] [Abstract][Full Text] [Related]
25. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).
Blansfield JA; Choyke L; Morita SY; Choyke PL; Pingpank JF; Alexander HR; Seidel G; Shutack Y; Yuldasheva N; Eugeni M; Bartlett DL; Glenn GM; Middelton L; Linehan WM; Libutti SK
Surgery; 2007 Dec; 142(6):814-8; discussion 818.e1-2. PubMed ID: 18063061
[TBL] [Abstract][Full Text] [Related]
26. Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome.
Weisbrod AB; Liewehr DJ; Steinberg SM; Patterson EE; Libutti SK; Linehan WM; Nilubol N; Kebebew E
Ann Surg Oncol; 2012 Jun; 19(6):2054-9. PubMed ID: 22350603
[TBL] [Abstract][Full Text] [Related]
27.
Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas.
Wang DS; Zhang DS; Qiu MZ; Wang ZQ; Luo HY; Wang FH; Li YH; Xu RH
Tumour Biol; 2011 Aug; 32(4):697-705. PubMed ID: 21479734
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
[TBL] [Abstract][Full Text] [Related]
30. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature.
Mortaji P; Morris KT; Samedi V; Eberhardt S; Ryan S
Fam Cancer; 2018 Apr; 17(2):275-280. PubMed ID: 28887784
[TBL] [Abstract][Full Text] [Related]
32. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.
Gurung B; Hua X; Runske M; Bennett B; LiVolsi V; Roses R; Fraker DA; Metz DC
Cancer Biol Ther; 2015; 16(2):219-24. PubMed ID: 25482929
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic insufficiency following pancreatectomy: Does underlying tumor syndrome confer a greater risk?
McDonald JD; Gupta S; Shindorf ML; Copeland A; Good ML; Sadowski SM; Nilubol N
Am J Surg; 2021 Feb; 221(2):465-471. PubMed ID: 32943182
[TBL] [Abstract][Full Text] [Related]
35. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.
Tirosh A; Killian JK; Petersen D; Zhu YJ; Walker RL; Blau JE; Nilubol N; Patel D; Agarwal SK; Weinstein LS; Meltzer P; Kebebew E
J Clin Endocrinol Metab; 2020 Oct; 105(10):3285-94. PubMed ID: 32706863
[TBL] [Abstract][Full Text] [Related]
36. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.
Chen HY; Zhang XY; Deng XY; Ge YL; Tang YQ; Cui H; Yang B; Pan Y; Shi D; Yu RS
AJR Am J Roentgenol; 2020 Aug; 215(2):390-397. PubMed ID: 32432906
[No Abstract] [Full Text] [Related]
37. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
38. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.
Gratian L; Pura J; Dinan M; Roman S; Reed S; Sosa JA
Ann Surg Oncol; 2014 Oct; 21(11):3515-21. PubMed ID: 24841347
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience.
Oleinikov K; Uri I; Jacob H; Epshtein J; Benson A; Ben-Haim S; Atlan K; Tal I; Meirovitz A; Maimon O; Lev-Cohain N; Mazeh H; Glaser B; Gross DJ; Grozinsky-Glasberg S
Endocrine; 2020 Apr; 68(1):222-229. PubMed ID: 32036501
[TBL] [Abstract][Full Text] [Related]
40. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
